Over the past 5 years, our laboratory has systematically developed a structure-guided library
approach to evolve new adeno-associated virus (AAV) capsids with altered tissue tropism …

Highlights•Glycan interactions are an essential first step in successful host infection by the
Parvovirinae subfamily of the Parvoviridae.•The binding sites for glycans overlap with …

CRISPR–Cas13 systems have been developed for precise RNA editing, and can potentially
be used therapeutically when temporary changes are desirable or when DNA editing is …

Post‐translational modifications in viral capsids are known to fine‐tune and regulate several
aspects of the infective life cycle of several viruses in the host. Recombinant viruses that are …

The capsid structures of most Adeno-associated virus (AAV) serotypes, already assigned to
an antigenic clade, have been previously determined. This study reports the remaining …

Highlights•Only intravascular delivery can truly change the course of systemic
diseases.•AAV has the capacity to escape from the blood and lead to bodywide gene …

All currently identified primary receptors of adeno-associated virus (AAV) are glycans.
Depending on the AAV serotype, these carbohydrates range from heparan sulfate …

Adeno-associated virus (AAV) vectors are preeminent in emerging clinical gene therapies.
Generalizing beyond the most tractable genetic diseases will require modulation of cell …

The adeno-associated viruses (AAVs), which are being developed as gene delivery vectors,
display differential cell surface glycan binding and subsequent tissue tropisms. For AAV …

Gene therapy aims to add, replace or turn off genes to help treat disease. To date, the US
Food and Drug Administration (FDA) has approved 14 gene therapy products. With the …